Cervical Cancer, Version 2.2015.


Journal Article

The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel's discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA's approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.

Full Text

Cited Authors

  • Koh, W-J; Greer, BE; Abu-Rustum, NR; Apte, SM; Campos, SM; Cho, KR; Chu, C; Cohn, D; Crispens, MA; Dorigo, O; Eifel, PJ; Fisher, CM; Frederick, P; Gaffney, DK; Han, E; Huh, WK; Lurain, JR; Mutch, D; Fader, AN; Remmenga, SW; Reynolds, RK; Teng, N; Tillmanns, T; Valea, FA; Yashar, CM; McMillian, NR; Scavone, JL

Published Date

  • April 2015

Published In

Volume / Issue

  • 13 / 4

Start / End Page

  • 395 - 404

PubMed ID

  • 25870376

Pubmed Central ID

  • 25870376

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0055


  • eng